Lead­ing a $60M launch round, RA Cap­i­tal backs an­oth­er 'toad ven­om' start­up

A year and a half af­ter div­ing head­first in­to the psy­che­del­ic col­lo­qui­al­ly known as “toad ven­om,” RA Cap­i­tal is back for more.

Lusaris Ther­a­peu­tics an­nounced its launch ear­ly Wednes­day morn­ing, com­bined with a $60 mil­lion Se­ries A led by RA Cap­i­tal. The biotech’s main fo­cus is look­ing at the psy­che­del­ic 5-MeO-DMT, a com­pound nat­u­ral­ly de­rived from plants and the Col­orado riv­er toad, to go af­ter treat­ment-re­sis­tant de­pres­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER